Risk factors for acute renal injury in living donor liver transplantation: Evaluation of the RIFLE criteria

Transplant International

Volumn 26, Issue 8, 2013, Pages 842-852

  Utsumi, Masashi ^a   Umeda, Yuzo ^a   Sadamori, Hiroshi ^a   Nagasaka, Takeshi ^a   Takaki, Akinobu ^a   Matsuda, Hiroaki ^a   Shinoura, Susumu ^a   Yoshida, Ryuichi ^a   Nobuoka, Daisuke ^a   Satoh, Daisuke ^a   Fuji, Tomokazu ^a   Yagi, Takahito ^a   Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

acute renal failure; liver transplantation; living donor; RIFLE criteria

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ARTICLE; BLEEDING; BODY WEIGHT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GRAFT REJECTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; LIVER TRANSPLANTATION; LIVING DONOR; LIVING DONOR LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; RIFLE CRITERIA; RISK ASSESSMENT; RISK FACTOR; SURGICAL MORTALITY; SURVIVAL RATE;

ACUTE RENAL FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; RIFLE CRITERIA;

ACUTE KIDNEY INJURY; ADULT; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; ORGAN SIZE; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK FACTORS;

EID: 84880285916     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12138     Document Type: Article

References (67)

1. Brown RS Jr, Lombardero M, Lake JR,. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996; 62: 1788.
2. Gainza FJ, Valdivieso A, Quintanilla N, et al,. Evaluation of acute renal failure in the liver transplantation perioperative period: incidence and impact. Transplant Proc 2002; 34: 250.
3. Narayanan Menon KV, Nyberg SL, Harmsen WS, et al,. MELD and other factors associated with survival after liver transplantation. Am J Transplant 2004; 4: 819.
4. Biancofiore G, Davis CL,. Renal dysfunction in the perioperative liver transplant period. Curr Opin Organ Transplant 2008; 13: 291.
5. Bilbao I, Charco R, Balsells J, et al,. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant 1998; 12: 123.
6. Cabezuelo JB, Ramirez P, Acosta F, et al,. Prognostic factors of early acute renal failure in liver transplantation. Transplant Proc 2002; 34: 254.
7. Cabezuelo JB, Ramirez P, Rios A, et al,. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69: 1073.
8. Lebron Gallardo M, Herrera Gutierrez ME, Seller Perez G, et al,. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004; 10: 1379.
9. Bellomo R, Ronco C, Kellum JA, et al,. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204.
10. Bell M, Liljestam E, Granath F, et al,. Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. Nephrol Dial Transplant 2005; 20: 354.
11. Hoste EA, Clermont G, Kersten A, et al,. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006; 10: R73.
12. Kuitunen A, Vento A, Suojaranta-Ylinen R, et al,. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg 2006; 81: 542.
13. Ferreira AC, Nolasco F, Carvalho D, et al,. Impact of RIFLE classification in liver transplantation. Clin Transplant 2010; 24: 394.
14. Paramesh AS, Roayaie S, Doan Y, et al,. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004; 18: 94.
15. Chen J, Singhapricha T, Hu KQ, et al,. Postliver transplant acute renal injury and failure by the RIFLE criteria in patients with normal pretransplant serum creatinine concentrations: a matched study. Transplantation 2011; 91: 348.
16. Tinti F, Umbro I, Mecule A, et al,. RIFLE criteria and hepatic function in the assessment of acute renal failure in liver transplantation. Transplant Proc 2010; 42: 1233.
17. Dahm F, Georgiev P, Clavien PA,. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant 2005; 5: 2605.
18. Kawasaki S, Makuuchi M, Matsunami H, et al,. Living related liver transplantation in adults. Ann Surg 1998; 227: 269.
19. Urata K, Kawasaki S, Matsunami H, et al,. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995; 21: 1317.
20. Umeda Y, Yagi T, Sadamori H, et al,. Preoperative proximal splenic artery embolization: a safe and efficacious portal decompression technique that improves the outcome of live donor liver transplantation. Transpl Int 2007; 20: 947.
21. Umeda Y, Matsuda H, Sadamori H, et al,. Leukoencephalopathy syndrome after living-donor liver transplantation. Exp Clin Transplant 2011; 9: 139.
22. Freire A, Hermida J, Tutor JC,. Comparison of blood tacrolimus concentrations in liver and kidney transplant recipients using ACMIA and MEIA immunoassays. Ups J Med Sci 2008; 113: 103.
23. Joo DJ, Jung I, Kim MS, et al,. Comparison of the affinity column-mediated immunoassay and microparticle enzyme immunoassay methods as a tacrolimus concentration assay in the early period after liver transplantation. Transplant Proc 2010; 42: 4137.
24. Ju MK, Chang HK, Kim HJ, et al,. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay? Transplant Proc 2008; 40: 3673.
25. Olejnik Y, Elaerts S, Bonardet A, et al,. Preliminary evaluation of a new chemiluminescence assay (Liaison Cyclosporine; DiaSorin Laboratories) allowing both C0 and C2 cyclosporine levels determination: comparison with RIA method. Transplant Proc 2005; 37: 172.
26. Terrell AR, Daly TM, Hock KG, et al,. Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinical chemistry analyzer. Clin Chem 2002; 48: 1059.
27. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1.
28. Levey AS, Eckardt KU, Tsukamoto Y, et al,. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089.
29. Morard I, Mentha G, Spahr L, et al,. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006; 20: 96.
30. Neuberger JM, Mamelok RD, Neuhaus P, et al,. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327.
31. Rodriguez-Peralvarez M, Germani G, Darius T, et al,. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2012; 12: 2797.
32. Shao ZY, Yan LN, Wang WT, et al,. Prophylaxis of chronic kidney disease after liver transplantation-experience from west China. World J Gastroenterol 2012; 18: 991.
33. Bradburn MJ, Clark TG, Love SB, et al,. Survival analysis Part III: multivariate data analysis-choosing a model and assessing its adequacy and fit. Br J Cancer 2003; 89: 605.
34. Yalavarthy R, Edelstein CL, Teitelbaum I,. Acute renal failure and chronic kidney disease following liver transplantation. Hemodial Int 2007; 11 (Suppl 3): S7.
35. Lafayette RA, Pare G, Schmid CH, et al,. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997; 48: 159.
36. de Mendonca A, Vincent JL, Suter PM, et al,. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000; 26: 915.
37. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
38. Boudjema K, Camus C, Saliba F, et al,. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11: 965.
39. Velidedeoglu E, Crawford MD, Desai NM, et al,. Predictors of late kidney dysfunction post-liver transplantation. Transplant Proc 2002; 34: 3315.
40. Sharma P, Welch K, Eikstadt R, et al,. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl 2009; 15: 1142.
41. O'Riordan A, Wong V, McCormick PA, et al,. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21: 2630.
42. Karie-Guigues S, Janus N, Saliba F, et al,. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl 2009; 15: 1083.
43. Thuluvath PJ,. When is diabetes mellitus a relative or absolute contraindication to liver transplantation? Liver Transpl. 2005: S25.
44. Trail KC, Stratta RJ, Larsen JL, et al,. Results of liver transplantation in diabetic recipients. Surgery 1993; 114: 650.
45. Pawarode A, Fine DM, Thuluvath PJ,. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741.
46. Campbell MS, Kotlyar DS, Brensinger CM, et al,. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005; 11: 1048.
47. Sanchez EQ, Gonwa TA, Levy MF, et al,. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004; 78: 1048.
48. Sezer S, Karakan S, Erismis B, et al,. Risk factors for kidney impairment and differential impact of liver transplantation on renal function. Transplant Proc 2011; 43: 609.
49. Fraley DS, Burr R, Bernardini J, et al,. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int 1998; 54: 518.
50. Xia VW, Du B, Braunfeld M, et al,. Preoperative characteristics and intraoperative transfusion and vasopressor requirements in patients with low vs. high MELD scores. Liver Transpl 2006; 12: 614.
51. Abbasoglu O,. Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol 2008; 14: 3117.
52. Kiuchi T, Kasahara M, Uryuhara K, et al,. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999; 67: 321.
53. Lee SK, Park JB, Kim SJ, et al,. Early postoperative renal dysfunction in the adult living donor liver transplantation. Transplant Proc 2007; 39: 1517.
54. Yamamoto S, Sato Y, Ichida T, et al,. Acute renal failure during the early postoperative period in adult living-related donor liver transplantation. Hepatogastroenterology 2004; 51: 1815.
55. Ogura Y, Hori T, El Moghazy WM, et al,. Portal pressure <15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl 2010; 16: 718.
56. Botha JF, Campos BD, Johanning J, et al,. Endovascular closure of a hemiportocaval shunt after small-for-size adult-to-adult left lobe living donor liver transplantation. Liver Transpl 2009; 15: 1671.
57. Yamada T, Tanaka K, Uryuhara K, et al,. Selective hemi-portocaval shunt based on portal vein pressure for small-for-size graft in adult living donor liver transplantation. Am J Transplant 2008; 8: 847.
58. Umeda Y, Yagi T, Sadamori H, et al,. Effects of prophylactic splenic artery modulation on portal overperfusion and liver regeneration in small-for-size graft. Transplantation 2008; 86: 673.
59. Troisi R, Ricciardi S, Smeets P, et al,. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Am J Transplant 2005; 5: 1397.
60. Sato Y, Yamamoto S, Oya H, et al,. Splenectomy for reduction of excessive portal hypertension after adult living-related donor liver transplantation. Hepatogastroenterology 2002; 49: 1652.
61. Kaido T, Mori A, Ogura Y, et al,. Lower limit of the graft-to-recipient weight ratio can be safely reduced to 0.6% in adult-to-adult living donor liver transplantation in combination with portal pressure control. Transplant Proc 2011; 43: 2391.
62. Bottiger Y, Brattstrom C, Tyden G, et al,. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999; 48: 445.
63. Jusko WJ, Thomson AW, Fung J, et al,. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17: 606.
64. Lindholm A,. Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther Drug Monit 1995; 17: 631.
65. Remuzzi G, Bertani T,. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13: 261.
66. Zhu M, Li Y, Xia Q, et al,. Strong impact of acute kidney injury on survival after liver transplantation. Transplant Proc 2010; 42: 3634.
67. De Simone P, Nevens F, De Carlis L, et al,. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008.